PHARMACOKINETICS
The maximum serum concentration (C max ) of cabozantinib is dose-dependent, ranging from 34.2 to 603 ng/mL following oral doses of 0.08 mg/kg to 1.28 mg/kg. 2 Cabozantinib is well absorbed orally and has a time to maximum concentration (T max ) of 5 hours. The terminal half life is ;55 to 100 minutes. [3] [4] [5] Cabozantinib is highly (99.7%) protein-bound and has a volume of distribution (V d ) of 349 L. When taken with food, the area under the time versus concentration curve (AUC) and C max increase by 57% and 47%, respectively. The drug is metabolized in the liver, by CYP3A4, to XL184 N-oxide. Cabozantinib is excreted hepatically (54%) and renally (27%). 5 Selected therapeutic regimens of cabozantinib appear in Table 1 
MECHANISM OF ACTION
Omacetaxine reversibly binds to the A-site cleft in the large ribosomal subunit of a type of archaeabacteria, interferes with chain elongation, and inhibits protein synthesis. In vitro, omacetaxine mediates inhibition of Mcl-1 and promotes apoptosis without the binding of Bcr-Abl. [22] [23] [24] [25] [26] [27] [28] [29] 
PHARMACOKINETICS
Omacetaxine is rapidly absorbed with a C max of 25.1 to 36.2 ng/mL and T max of 0.55 to 0.6 hours. The V d is 126.8 L/m 2 . The apparent clearance following the first dose is 13.5 L/h/m 2 and 10.5 L/h/m 2 at steady state. The mean half-life (t 1/2 ) of elimination is 7 hours. After the first dose, the apparent volume of distribution is 126.8 L/m 2 . The AUC during a dosing interval at steady state is 188 ng/mL. Omacetaxine is hydrolyzed by plasma esterases to the inactive metabolites 49-demethyl-homoharringtonine (49-DMHHT) and cephalotaxine with minimal hepatic metabolism. Urinary excretion of unchanged omacetaxine accounted for 12% to 15% of the dose as unchanged drug. 22 Selected therapeutic regimens of omacetaxine appear in Table 2 . E. Hematologic: Anemia 22% to 100%, 24, 25, 27 (grade 3 or 4) 22% to 39% [24] [25] [26] [27] 29 ; febrile neutropenia 7% to 12% 26, 29 ; neutropenia 22% to 54%, [24] [25] [26] [27] (grade 3 or 4) 22% to 47% [24] [25] [26] [27] 31 ; thrombocytopenia 56% to 82%, [24] [25] [26] [27] [28] (grade 3 or 4) 43% to 76% [24] [25] [26] [27] [28] ; lymphopenia 18%, 25 (grade 3 or 4) 16%. 24 F. Infection: Bacterial, viral, fungal, and nonspecified 42%, 24 (grade 3 or 4) 2% to 14%. 24 Note: CIVI 5 continuous (24 hour) intravenous infusion; IM 5 intramuscular; IV 5 intravenous; SC 5 subcutaneous. a Conforms to dosing information listed in the manufacturer's labeling.
